West Pharmaceutical Services (WST) Common Equity (2009 - 2026)

West Pharmaceutical Services (WST) has reported Common Equity for 18 consecutive years, with $3.0 billion the latest figure, recorded in Q2 2026.

• Quarterly Common Equity rose 2.09% year-over-year to $3.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.0 billion (up 2.09% YoY) and the FY2025 annual result came in at $3.2 billion, up 18.41% from the prior year.
• Common Equity held at $3.0 billion in Q2 2026 per WST's latest filing, from $3.0 billion in the prior quarter.
• Over the last five years, Common Equity for WST reached as high as $3.2 billion in Q4 2025 and fell as low as $2.3 billion in Q1 2022.
• A 5-year average of $2.8 billion and a median of $2.7 billion in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity rose 27.18% — and 2024, when it slipped 6.9%.
• Year by year, Common Equity stood at $2.7 billion in 2022, then advanced by 7.3% to $2.9 billion in 2023, then dropped by 6.9% to $2.7 billion in 2024, then increased by 18.41% to $3.2 billion in 2025, then retreated by 5.85% to $3.0 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.0 billion, $3.0 billion, and $3.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.